Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


In the intensive care unit (ICU) setting, where highly variable and insufficient drug efficacies, as well as frequent and unpredictable adverse drug reactions (ADRs) occur, pharmacogenomics (PGx) offers an opportunity to improve health outcomes. However, PGx has not been fully evaluated in the ICU, partly due to lack of knowledge of how genetic markers may affect drug therapy. To fill in this gap, we conducted a review to summarize the PGx information for the medications commonly encountered in the ICU.

Original languageEnglish (US)
Article number1436
JournalFrontiers in Pharmacology
StatePublished - Dec 4 2018

Bibliographical note

Funding Information:
SZ is supported by a research grant from Shanghai Municipal Commission of Health and Family Planning Research Project of China (20164Y0170), a grant from “the Fundamental Research Funds for the Central Universities of China” (22120180394), and a research grant “Pandeng Plan” from Shanghai Tenth People’s Hospital of China ( RH receives a NIH/NCI grant [1R01CA204856-01A1] and a research grant from the Avon Foundation for Women. She also received support from the NIH/NIGMS [grants K08GM089941, U01GM61393] and the NIH/NCI [grant R21 CA139278].

Publisher Copyright:
© Copyright © 2018 Zhou, Skaar, Jacobson and Huang.


  • adverse drug reaction
  • intensive care unit
  • personalized medicine
  • pharmacogenetics
  • pharmacogenomics


Dive into the research topics of 'Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit'. Together they form a unique fingerprint.

Cite this